Special Feature
Three Questions to Ask About Your Life Sciences Patents
In March 2013, with the America Invents Act, the US will move to a first-inventor-to-file patent system. Marian T. Flattery and Michael J. Flibbert highlight the three questions that will be important to ask before filing  ...Read more

AIDS Focus
Challenges in the March Toward an AIDS-Free Generation
FDA's approval of Truvada, a once-a-day oral combination of tenofovir and emtricitabine, for pre-exposure prophylaxis (or PrEP, a method for preventing HIV infection) arrived during a chorus of optimism surrounding major developments in the fight against AIDS ...Read More

AIDS Focus
Antiretroviral Drug Breakthrough Tempered by Home Truths
The prospect that antiretroviral drugs could prevent HIV infection in high-risk populations was the big news emerging from last month’s International AIDS Conference in Washington, DC. But the news raises a tricky ethical question ...Read More

Advertisement Pharmaceutical companies are effecting a paradigm shift in their focus towards emerging markets driven by the growing economies of these markets and the steady decline of growth opportunities in the developed markets. Varied demography, varied government spending on health and differences in the regulatory environments in individual countries of the emerging markets require global pharmaceutical companies to create and implement specific and custom strategies to succeed in these markets. The whitepaper examines the current trends, requirements and outsourcing solutions for effective medical communication approach for the emerging markets. www.sciformix.com/ROI.php

Biopharma
Biomedical Innovation in Trouble
A bleak picture of the "state of biomedical innovation" was painted by experts at a seminar in June sponsored by the Brookings Institution Engelberg Center for Health Care Reform ...Read more

European Patients Organizations Wade into the Pricing Debate

Emerging Pharma Leaders: Sanofi's David Ford

GSK Goes DTC for London Olympics